Home Research Staff Publications

Publications

Prof. Dr. Gerhard Gründer

Augustin M, Schoretsanitis G, Pfeifer P, Gründer G, Liebe C, Paulzen M. Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations. Schizophr Res. 2019 210:143-148. Epub 2019 Jun 7.
Brown D, Nakagome K, Cordes J, Brenner R, Gründer G, Keefe RSE, Riesenberg R, Walling DP, Daniels K, Wang L, McGinniss J, Sand M. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. Schizophr Bull. 2019 45(2):350-359. Epub 2018 May 1.
Deuse L, Wudarczyk O, Rademacher L, Kaleta P, Karges W, Kacheva S, Gründer G, Lammertz SE. Peripheral Oxytocin Predicts Higher-Level Social Cognition in Men Regardless of Empathy Quotient. Pharmacopsychiatry. 2019 52(3):148-154. Epub 2018 Mar 28.
Gründer G, Cumming P. The downside of downregulation. Brain. 2019 142(6):1500-1502.
Gründer P, Augustin M, Paulzen M, Gründer G. Influence of Kidney Function on Serum Risperidone Concentrations in Patients Treated With Risperidone. J Clin Psychiatry. 2019 80(6)
Hansson AC, Gründer G, Hirth N, Noori HR, Spanagel R, Sommer WH. Dopamine and opioid systems adaptation in alcoholism revisited: Convergent evidence from positron emission tomography and postmortem studies. Neurosci Biobehav Rev. 2019 106:141-164. Epub 2018 Sep 19.
Kowalewski C, Haen E, Hiemke C, Ridders F, Endres K, Gründer G, Paulzen M, Schoretsanitis G. Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine. Int Clin Psychopharmacol. 2019 34(5):241-246. Epub 2019 May 14.
Paulzen M, Stingl JC, Augustin M, Saßmannshausen H, Franz C, Gründer G, Schoretsanitis G. Comprehensive Measurements of Intrauterine and Postnatal Exposure to Lamotrigine. Clin Pharmacokinet. 2019 58(4):535-543. Epub 2018 Sep 25.
Schoretsanitis G, Augustin M, Saßmannshausen H, Franz C, Gründer G, Paulzen M. Antidepressants in breast milk; comparative analysis of excretion ratios. Arch Womens Ment Health. 2019 22(3):383-390. Epub 2018 Aug 16.
Schoretsanitis G, Haen E, Gründer G, Hiemke C, Endres K, Ridders F, Correll CU, Paulzen M. Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database. Eur J Clin Pharmacol. 2019 75(8):1109-1116. Epub 2019 Apr 9.
Schoretsanitis G, Haen E, Hiemke C, Endres K, Ridders F, Veselinović T, Gründer G, Paulzen M. Pharmacokinetic correlates of venlafaxine: associated adverse reactions. Eur Arch Psychiatry Clin Neurosci. 2019 269(7):851-857. Epub 2018 Mar 28.
Tatsch K, Buchert R, Bartenstein P, Barthel H, Boecker H, Brust P, Drzezga A, la Fougère C, Gründer G, Grünwald F, Krause BJ, Kuwert T, Langen KJ, Rominger A, Sabri O, Schreckenberger M, Meyer PT. [Dopamine Transporter SPECT with I-123 labelled FP-CIT (DaTSCANTM)]. Nuklearmedizin. 2019 58(1):5-16.
Unterecker S, Hefner G, Baumann P, Gründer G, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Haen E, Havemann-Reinecke U, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Waschgler R, Zernig G, Zurek G, Hiemke C. [Therapeutic drug monitoring in neuropsychopharmacology : Summary of the consensus guidelines 2017 of the TDM task force of the AGNP]. Nervenarzt. 2019 90(5):463-471. Epub 2018 Nov 16.
Unterecker S, Hefner G, Baumann P, Gründer G, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Haen E, Havemann-Reinecke U, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Waschgler R, Zernig G, Zurek G, Hiemke C. [Erratum to: Therapeutic drug monitoring in neuropsychopharmacology : Summary of the consensus guidelines 2017 of the TDM task force of the AGNP]. Nervenarzt. 2019 90(9):958-960. Epub 2019 Jul 15.
Veselinović T, Scharpenberg M, Heinze M, Cordes J, Mühlbauer B, Juckel G, Habel U, Rüther E, Timm J, Gründer G, NeSSy Study Group . Disparate effects of first and second generation antipsychotics on cognition in schizophrenia - Findings from the randomized NeSSy trial. Eur Neuropsychopharmacol. 2019 29(6):720-739. Epub 2019 Apr 10.
Veselinović T, Scharpenberg M, Heinze M, Cordes J, Mühlbauer B, Juckel G, Rüther E, Paulzen M, Haen E, Hiemke C, Timm J, Gründer G, NeSSy Study Group . Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia: Results From the Randomized NeSSy Trial. J Clin Psychopharmacol. 2019 39(6):550-560.


Zentralinstitut für Seelische Gesundheit (ZI) - https://www.zi-mannheim.de